Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Open accessThe DOI matches its Crossref record; 229 of the 234 references it cites were found in a registry or an index; 29 of the 182 sources its claims cite were checked for support.
Abstract
Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other’s efficacy, paving the way for promising future therapeutic advancements.
Overview
CoChat Summary
TL;DR
This narrative review summarizes current and emerging immunotherapy for colorectal cancer (CRC), including immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), vaccines, and telomere/telomerase-targeted strategies. It highlights dMMR/MSI-H as the main immunotherapy-responsive subset and proposes telomere length and telomerase activity as potential prognostic/predictive biomarkers and adjunct targets.
Key findings
- dMMR/MSI-H is identified in roughly 15% of all CRC patients and 5% of metastatic CRC (mCRC) patients; by stage, it accounts for about 15–18% of stage II, ~10% of stage III, and ~5% of stage IV cases. ICIs benefit this subset, but approximately 15–29% develop immune resistance.
- FDA-approved ICIs for CRC include nivolumab (since 1 August 2017 for MSI-H/dMMR mCRC, based on CheckMate 142), pembrolizumab (since 29 June 2020 as first-line for unresectable or metastatic MSI-H/dMMR CRC, based on KEYNOTE-177), and nivolumab plus ipilimumab for previously treated MSI-H/dMMR mCRC. Atezolizumab did not achieve its primary endpoint of improved overall survival in previously treated mCRC.
- As of January 2024, 14 clinical trials were underway assessing TIL cells for CRC; TIL therapy produced objective regression of multiple lung metastatic lesions in mCRC after infusion of HLA-C*08:02-restricted TILs targeting KRAS G12D.
- Telomere/telomerase findings: annual telomere shortening is approximately 20–40 base pairs; telomerase activity is detected in 80–100% of CRC tumor samples versus 9–53% of normal mucosa samples; high TERT and/or telomerase activity is typically associated with poorer prognosis. Longer telomere length was associated with better overall survival regardless of cancer type in one cited study, but had no effect on response to ICI therapy.
Methods
- Design: narrative review of immunotherapy and telomere-targeted therapies in CRC.
- Data: published preclinical and clinical literature, including cited phase II/III trials, meta-analyses, and ClinicalTrials.gov registrations.
- Analysis: qualitative synthesis of immune checkpoint biology, ACT, vaccine platforms, biomarkers, and telomere/telomerase dynamics; no systematic search strategy, meta-analysis, or primary patient data are described.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, inclusion criteria, or risk-of-bias assessment, so selection and publication biases cannot be excluded.
- Evident from the text: many cited findings come from heterogeneous settings (preclinical models, phase I/II trials, retrospective studies, and ongoing trials), and proposed synergies between telomere status and ICIs/ACT are largely presented as hypotheses rather than tested in the reviewed clinical trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 4 Not valid · 117 Not checked · 15 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast to ICIs that greatly exert their action through antagonism of suppressor T-cell receptors, ACT providesits anticarcinogenic effect through isolating the expansion of a great volume of T cells that may overcome certain suppressive immunomodulatory parameters [19].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Supportedcites [19] Yi X. Hu W. Advances in adoptive cellular therapy for colorectal cancer: A narrative review Ann. Transl. Med. 2022 10 1404 10.21037/atm-22-6196 36660664 PMC9843349 source
The Introduction (p.1) of Yi & Hu 2022 states verbatim in substance: 'Unlike ICIs that block T-cell suppressor receptors, ACT exhibits antitumor activity by isolated expansion of large numbers of T cells, which may allow bypassing certain suppressive immunomodulatory factors.' The citing sentence reproduces this contrast (ICI = antagonist of suppressor T-cell receptors; ACT = isolated expansion of a large T-cell volume overcoming suppressive immunomodulatory parameters) with the same hedged modality ('may'). No additional reading was needed. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, despite the high rate of durable responses, a fraction of them will develop immune resistance that can outweigh prolonged survival outcomes (approximately 15–29%) [12,15,16].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Supportedcites [12] Borelli B. Antoniotti C. Carullo M. Germani M.M. Conca V. Masi G. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability Cancers 2022 14 4974 10.3390/cancers14204974 36291761 PMC9599678 source
The Introduction states that, despite durable responses and prolonged survival with ICIs in dMMR/MSI-H metastatic colorectal cancer, 15–29% of patients experience primary refractoriness or only short-term clinical benefit. Section 4 also describes primary and acquired resistance, supporting the citing sentence’s broader reference to immune resistance. (LLM, conf=0.92)
- Partly supportedcites [15] André T. Shiu K.-K. Kim T.W. Jensen B.V. Jensen L.H. Punt C. Smith D. Garcia-Carbonero R. Benavides M. Gibbs P. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer N. Engl. J. Med. 2020 383 2207 2218 10.1056/NEJMoa2017699 33264544 sourceExperimental — accuracy not yet measured
The Radiographic Response section reports progressive disease as the best response in 29.4% of pembrolizumab-treated patients, and the Discussion calls nonresponse in a subgroup “apparent resistance.” The Duration of Response section reports durable responses, but the paper does not establish that 15–29% developed resistance after responding or that resistance outweighed a prolonged-survival benefit. (LLM, conf=0.86)
- Partly supportedcites [16] Lenz H.J. Van Cutsem E. Limon M.L. Wong K.Y.M. Hendlisz A. Aglietta M. García-Alfonso P. Neyns B. Luppi G. Cardin D.B. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study J. Clin. Oncol. 2022 40 161 170 10.1200/JCO.21.01015 34637336 sourceExperimental — accuracy not yet measured
The Efficacy section reports durable responses and a 13–16% progressive-disease rate with first-line nivolumab plus ipilimumab. The Discussion reports a 29% progressive-disease rate with pembrolizumab and suggests possible intrinsic resistance, but it does not establish that 15–29% develop resistance after responding or that resistance outweighs prolonged survival. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, it is also well established that immune responses may be negatively affected in cases of telomere attrition [27,28].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 1. Introduction
What the sources say
- Could not verifycites [27] Nikolouzakis T.K. Vakonaki E. Stivaktakis P.D. Alegakis A. Berdiaki A. Razos N. Souglakos J. Tsatsakis A. Tsiaoussis J. Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes Front. Oncol. 2021 11 683605 10.3389/fonc.2021.683605 34262868 PMC8274420 sourceExperimental — accuracy not yet measured
Our copy of Nikolouzakis et al. (2021) covers telomerase activity (TA) and telomere length in peripheral blood lymphocytes as prognostic biomarkers in metastatic/locally advanced CRC; the Introduction (telomerase/telomere paragraph) links shorter telomeres per cell cycle to 'cellular senescence' as a barrier against cancer, but no passage ties telomere attrition to impaired immune responses. Searches for 'immune response / immunity', 'lymphocyte senescence', and 'telomere attrition' returned only TA results, hTERT signalling pathways (Discussion), the control-group exclusion of autoimmune disease/immune-modifying medication, and reference lists — none state the claim. Nothing contrary is said either, so the point is simply not addressed by this source. (LLM, conf=0.70)
- Supportedcites [28] Weng N.P. Telomeres and immune competency Curr. Opin. Immunol. 2012 24 470 475 10.1016/j.coi.2012.05.001 22626625 PMC3423542 source
The Concluding remarks section states that shortened telomeres in lymphocytes are conceived to have a detrimental impact on their ability to combat pathogens and that 'lymphocytes with short telomeres will have reduced ability to mount a strong and sustained immune response.' The section 'Short telomeres of leukocytes associated with aging and immune dysfunctions' likewise links telomere attrition to replicative impairment/exhaustion of viral-reactive T cells, and 'Potential applications of telomere length measurement in leukocytes' extends this to poor vaccine responses in the elderly. The hedged phrasing of the claim ('may be negatively affected') is matched or exceeded by our copy. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, MSI-H results in the upregulation of immune checkpoint proteins (like PD-1 and PD-L1), facilitating immune evasion via tumor-infiltrating lymphocytes, rather than tumor cells [71].”
- Also stated in: § 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1) · hedged
“Interestingly, current data suggest that cancers with MSI-H exhibit upregulation of immune checkpoint proteins like PD-1 and PD-L1, facilitating immune evasion through tumor-infiltrating lymphocytes rather than tumor cells themselves [71].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 3. Immune Response in CRC
What the sources say
- Partly supportedcites [71] Llosa N.J. Cruise M. Tam A. Wicks E.C. Hechenbleikner E.M. Taube J.M. Blosser R.L. Fan H. Wang H. Luber B.S. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints Cancer Discov. 2015 5 43 51 10.1158/2159-8290.CD-14-0863 25358689 PMC4293246 sourceExperimental — accuracy not yet measured
The Results report higher PD-1 expression on lymphocytes and higher PD-L1 expression in MSI than MSS tumors; the Discussion links these checkpoints to adaptive resistance. However, the Results identify infiltrating myeloid cells—not lymphocytes—as the predominant source of PD-L1. The Discussion also allows that tumor cells may express PD-L1 below the detection limit of the assay. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1) · hedged
Every source the paper cites for this claim was checked and supports it.
In the paper
“For gastrointestinal tumors, such as CRC, the primary hurdle in developing TIL therapy may not lie in the in vitro expansion of bulk TILs but rather in the ability to select and enrich tumor-reactive T cells [142].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 7. Adoptive Cell Therapy (ACT) > 7.2. Tumor-Infiltrating Lymphocyte (TIL) Therapy
What the sources say
- Supportedcites [142] Turcotte S. Gros A. Hogan K. Tran E. Hinrichs C.S. Wunderlich J.R. Dudley M.E. Rosenberg S.A. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy J. Immunol. 2013 191 2217 2225 10.4049/jimmunol.1300538 23904171 PMC3748336 source
The Discussion directly states that the main challenge for TIL therapy in metastatic gastrointestinal cancers may be selecting and enriching tumor-reactive T cells, rather than expanding bulk TILs in vitro. The Clinical-scale TIL expansion section also reports successful expansion of GI cancer-derived TILs. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
78 more claims · 12 with their cited sources checked
Create a free account to see all 159 claims and to verify the 153 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 37
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that is often used to treat MSI High (MSI-H) or dMMR tumors [37].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“This subset of CRC exhibits high immunogenicity due to increased mutational burden, inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [37,38].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“It has been shown that PD-L1 or PD-L2, acting through their ligation to PD-1, may induce anti-cancer immune responses.”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 4. Immune Evasion of CRC
“Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [85].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 10. Dynamics of Telomere Length
“Shelterin is a complex of proteins comprising six subunits—TRF1, TRF2, TIN2, TPP1, and POT1 [169].”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 10. Dynamics of Telomere Length
“TRF1, TRF2, TIN2, TPP1, and POT1”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“PD-1, also known as CD279”
§ Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy > 5. Immune Checkpoints > 5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)
“The PD-1 ligand (PD-L1), also known as CD279 and B7-H1”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Programmed Death-Ligand 1 (PD-L1) monoclonal antibodies used against Programmed Death 1 (PD-1) or Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) dramatically augmented the therapeutic armamentarium while also providing significant positive re-appreciation of prognosis across several solid tumors [9–11].”
BackgroundPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“In fact, solid tumors such asnon-small cell lung cancer (NSCLC) and melanoma have retrieved significant therapeutic results from immunotherapy [7,8].”
BackgroundOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“In contrast, tumors with a proficient MMR (pMMR) or MSS phenotype exhibit low immunogenicity [44], leading to decreased expression of checkpoint proteins and low or no T-cell tumor infiltration, explaining their intrinsic resistance to ICIs.”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“…can activate a host’s immune system via a complex pathway encompassing not only the adaptive immune system (T and B lymphocytes) but also the innate system (such as mast cells, dendritic cells (DCs), macrophages, natural killer (NK) cells, neutrophils, and myeloid-derived suppressor cells) [57].”
BackgroundThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675 · cited 1×
“Programmed Death-Ligand 1 (PD-L1) monoclonal antibodies used against Programmed Death 1 (PD-1) or Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) dramatically augmented the therapeutic armamentarium while also providing significant positive re-appreciation of prognosis across several solid tumors [9–11].”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“Additionally, studies by Allison et al. using murine colon carcinoma and fibrosarcoma models demonstrated that co-administration of anti-CTLA-4 antibodies with tumor lysate-loaded dendritic cells can reduce Tregs, increase CD8+ lymphocytes, inhibit metastatic growth, and prolong survival [121].”
BackgroundColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“A series of studies have shown that the identification of tumor-specific T cells is linked to favorable outcomes in various human cancers [63].”
BackgroundIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256 · cited 1×
“PD-1, also known as CD279, was initially discovered in 2B4-11 (murine T-cell hybridoma) and interleukin-3 (IL-3)-deprived LyD9 (murine hematopoietic progenitor) cell lines in 1992 [88].”
BackgroundCellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225 · cited 1×
“…study, Nikolouzakis et al. showed that TL in PBLs from patients with mCRC tends to decrease with age (especially for patients over 75 years old) when compared to healthy individuals of the same age, while chemotherapy seemed to also have a negative impact on the mean TL of mCRC patients [29].”
ResultCar t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“Detailed information about these trials can be found on the ClinicalTrials.gov website (NCT03935893, NCT04426669, NCT03610490, NCT02980146, NCT01174121, NCT05573035, NCT05902520, NCT05610592, NCT04622423, NCT05524012, NCT03960021, NCT03904537, NCT00019084, NCT05576077).”
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183 · cited 1×
“The first steps of a MS profile can be evaluated using the Bethesda gene status, which includes 5 MS loci (D5S346, BAT26, D17S250, BAT25, and D2S123) [37]; however, a number of researchers have proposed an extended version of this with 10 loci.”
MethodPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“[12,15,16].”
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072 · cited 1×
“[73].”
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 2×
“…to enhance the activity of effector T cells while suppressing regulatory T cells, resulting in net inhibition of tumor progression Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
BackgroundMethodCancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 2×
“As for the vaccines created for infectious diseases, the primary objective of anti-cancer vaccines is to promote an immune response aiming to eradicate tumors and establish continuous monitoring to prevent their recurrence.”
BackgroundAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506 · cited 3×
“This process enables the modified cells to specifically target tumor cells, triggering autologous immune responses to eradicate them [18].”
BackgroundInfluentialPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“The authors assumed that the observed difference in OS can be explained by the fact that shorter telomeres may be associated with increased non-tumor-related mortality.”
BackgroundSlipped-strand mispairing: a major mechanism for DNA sequence evolution.
(1987) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a040442 · Cited by 2,245 · cited 1×
“It is observed that MSs are susceptible to duplication errors through strand slippage during DNA synthesis [31].”
BackgroundPD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed · Cited by 2,217
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052 · cited 1×
“Current research in CRC epigenetics highlights the important role of telomeres and their regulating enzyme, telomerase, not only as clinical biomarkers but also as potential therapeutic targets [20–27].”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · cited 1×
“This is possible because of the JAK1/JAK2 and STAT1 pathways, leading to tumor cell survival and disease progression [99,100].”
BackgroundLandon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
How Shelterin Protects Mammalian Telomeres
Palm, W., & de Lange, T. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130350 · Cited by 1,802 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · cited 1×
“Func-tionally, PD-1 is able to exert its inhibitory effects on both innate and adaptive immune responses and is able to activate macrophages, T cells, B lymphocytes, DCs, NK, and monocytes [90].”
BackgroundEpidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565 · cited 1×
“Cross-sectional analyses demonstrate progressive shortening of TL IN with advancing age in leukocytes or peripheral blood mononuclear cells (PBMCs), as well as in isolated granulocytes and lymphocytes (CD4 and CD8 T cells, and B cells) [227].”
BackgroundThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528 · cited 1×
“In addition, if inflammation is present, PD-L1 can be expressed on certain epithelial cells [96].”
BackgroundSaam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476 · cited 1×
“An MSI-H/dMMR phenotype is identified in roughly 15–18% of stage II CRCs, and in stage III and IV disease settings, it accounts for approximately 10% and 5% of cases, respectively [39].”
BackgroundAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · cited 1×
“ICIs such as anti-CTLA-4, anti-PD-1, and anti-PD-L1 can bind to these co-inhibitory receptors, effectively reviving the anti-cancer immune response [122].”
BackgroundImmune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · cited 1×
“Shelterin is a complex of proteins comprising six subunits—TRF1, TRF2, TIN2, TPP1, and POT1 [169].”
BackgroundNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · cited 1×
“CD8+ T cells and CD4+ effector T cells have demonstrated anti-cancer potential, while regulatory T cells (CD4+ CD25+ Tregs) have been shown to be able to contribute to the attenuated immune response exhibited in cancer [65,66].”
BackgroundLe, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980 · cited 1×
“On the T-cell membrane, CTLA-4 exhibits higher binding avidity to B7 molecules compared to CD28, thus competing with CD28 to regulate costimulation and induce anergy [115].”
BackgroundPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · cited 1×
“However, depletion of Tregs alone does not enhance anti-tumor responses; rather, a combination of enhanced effector T cell function and the inhibition of Treg activity is necessary for maximal anti-tumor activity [119].”
BackgroundDiaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 945
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944 · cited 3×
“[130].”
BackgroundTelomeres and telomerase: three decades of progress
Shay, J. W., & Wright, W. E. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0099-1 · Cited by 924 · cited 1×
“In cancer research, significant attention has been given to understanding the regulation of the human telomerase reverse transcriptase (hTERT), which plays a crucial role in cancer.”
BackgroundHuman Telomerase and Its Regulation
Cong, Y.-S., Wright, W. E., & Shay, J. W. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.3.407-425.2002 · Cited by 898 · cited 1×
“The EGFR pathway plays a crucial role in regulating the telomerase complex [215].”
BackgroundCarreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896 · cited 1×
“Studies have demonstrated that PD-1 shares approximately 13%, 15%, and 20% similarity with induced T-cell co-stimulators CD28 and CTLA4, accordingly [89].”
BackgroundSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 1×
“Anti-CTLA-4antibodies have been shown to deplete intratumoral Tregs, possibly through antibody-dependent cell-mediated cytotoxicity, leading to enhanced anti-tumor responses [120].”
BackgroundHuman cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843 · cited 1×
“If so, tumor cells can evade anti-cancer immune responses [97].”
BackgroundRectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0051 · Cited by 827 · cited 1×
“Recent years have seen a surge in research focused on the comprehensive treatment of CRC, with combination therapy involving targeted agents emerging as the primary treatment approach for metastatic CRC (mCRC) patients [5,6].”
BackgroundChronic inflammation induces telomere dysfunction and accelerates ageing in mice
Jurk, D., Wilson, C., Passos, J. F., Oakley, F., Correia-Melo, C., Greaves, L., Saretzki, G., Fox, C., Lawless, C., Anderson, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5172 · Cited by 819 · cited 1×
“As the diagnosis of CRC increasingly affects a younger population and the prevalence of advanced stages of the disease rises, the imperative to expand CRC treatment modalities becomes ever more pressing.”
BackgroundVenderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · cited 2×
“However, the prognostic significance of MSI/dMMR in such stages is debated [40].”
BackgroundTelomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754 · cited 1×
“This technique is the most accurate and precise compared to others since it measures each telomere end in each chromosome in each cell, avoiding the false measurement of the interstitial telomere regions of the chromosomes, and allows the recognition of telomere-free ends which lead to chromosomal…”
MethodTelomeres in cancer: tumour suppression and genome instability
Maciejowski, J., & de Lange, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.171 · Cited by 745 · cited 1×
“Some researchers, such as Luu et al. [197] and Peacock et al. [198], have reported that the risk of developing CRC seems to be higher in people with longer telomeres.”
BackgroundLenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundCancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715 · cited 1×
“On the contrary, peptide vaccines are suggested to provoke an immune reaction against a particular identified tumor antigen.”
BackgroundRufer, N., Brümmendorf, T. H., Kolvraa, S., Bischoff, C., Christensen, K., Wadsworth, L., Schulzer, M., & Lansdorp, P. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.2.157 · Cited by 709 · cited 1×
“…with dMMR/MSI-H and/or mCRC. Numerous investigations are ongoing to broaden the applicability of CRC immunotherapy, exploring additional biomarkers or microenvironments that modulate the anti-tumor immune response and evaluating immunotherapy, particularly ICIs, as both a primary and…”
BackgroundAndré, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683 · cited 1×
“This group is estimated to be around 15% of all CRC patients and 5% of those with metastatic CRC (mCRC) [13,14].”
BackgroundThe role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504542 · Cited by 624 · cited 1×
“Detailed information about these trials can be found on the ClinicalTrials.gov website (NCT03935893, NCT04426669, NCT03610490, NCT02980146, NCT01174121, NCT05573035, NCT05902520, NCT05610592, NCT04622423, NCT05524012, NCT03960021, NCT03904537, NCT00019084, NCT05576077).”
Systematic analysis of telomere length and somatic alterations in 31 cancer types
Barthel, F. P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X., Amin, S. B., Akdemir, K. C., Seth, S., Song, X., Wang, Q., et al. (2017) · Nature Genetics · doi:10.1038/ng.3781 · Cited by 614 · cited 1×
“However, Nikolouzakis et al., studying TA in PBLs from 28 patients with mCRC, described that TA presented a significant trend of increase ( p = 0.07) in patients with progressive disease at the middle of their treatment when compared with that before the initiation [27].”
ResultInfluentialIntracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement
Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L., & Mittler, R. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80480-x · Cited by 609 · cited 1×
“CTLA-4 exerts its inhibitory effects by influencing T-cell function, particularly during the priming phase of immune responses [113].”
BackgroundTherapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597 · cited 1×
“This is because HLA molecules are expressed in a variety of super-types and only a particular HLA-super-type can recognize a specific antigen.”
BackgroundEgen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535 · cited 1×
“Its expression is upregulated in response to stronger stimulatory signals through the T-cell receptor (TCR), leading to translocation to the T cell surface [114].”
BackgroundImmunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · cited 1×
“…revealed two noteworthy trends that are presently shaping and will persistently influence cancer therapy in the foreseeable future: the employment of immune cell markers for predicting cancer outcomes and the targeting of diverse aspects of the immune system to induce an anti-tumor immune response.”
BackgroundThe Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460 · cited 1×
“This sequence of events is referred to as the cancer–immune cycle [62].”
BackgroundVaiserman, A., & Krasnienkov, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.630186 · Cited by 454 · cited 1×
“Bertorelle et al. showed that stage II CRC patients with lower levels of hTERT had better OS, while its presence at higher levels was correlated with a poor response to chemotherapy (as an independent prognostic factor) and with a higher risk of disease recurrence and death [207].”
BackgroundYuan, X., Larsson, C., & Xu, D. (2019) · Oncogene · doi:10.1038/s41388-019-0872-9 · Cited by 450 · cited 1×
“An explanation they provide dictates that there is an increased risk of mutational accumulation with carcinogenic potential as a result of longer telomeres.”
BackgroundIdentifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · cited 1×
“Between the extracellular domain (antigen-binding) and the TM domain is the hinge region (also known as the spacer region).”
BackgroundThe determinants of tumour immunogenicity
Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3246 · Cited by 441 · cited 1×
“However, clinical trials have shown mixed results even though the overall trend was positive [155,156].”
ResultTelomerase modulates expression of growth-controlling genes and enhances cell proliferation
Smith, L. L., Coller, H. A., & Roberts, J. M. (2003) · Nature Cell Biology · doi:10.1038/ncb985 · Cited by 438 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundNatural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438 · cited 1×
“In a typical scenario, innate immune cells like NK cells identify the absence of MHC-I surface molecules on cancer cells, leading to the active elimination of cancer cells and subsequent recruitment of other inflammatory cells through cytokine production [60].”
BackgroundJocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15590-6 · Cited by 434 · cited 1×
“Viral vector vaccines: Due to the relatively low stimulating capacity of peptide antigen vaccines, several teams have tried to augment the generated immune response via the use of viral or bacterial vectors.”
BackgroundStaron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385 · cited 1×
“The transcription of PD-1 is induced by various transcription factors, among which are NOTCH, interferon (IFN), regulatory factor 9 (IRF9), nuclear factor of activated T cells (NFAT), and Forkhead box protein (FOX) O1 [91].”
BackgroundMicrosatellite instability and colorectal cancer prognosis
Benatti, P., Gafà, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., Maestri, I., Guerzoni, L., Roncucci, L., Menigatti, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1030 · Cited by 379 · cited 1×
“This group is estimated to be around 15% of all CRC patients and 5% of those with metastatic CRC (mCRC) [13,14].”
BackgroundTelomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundThe power of exercise: buffering the effect of chronic stress on telomere length
Puterman, E., Lin, J., Blackburn, E., O'Donovan, A., Adler, N., & Epel, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010837 · Cited by 339 · cited 1×
“Substantial progress has been achieved in elucidating the immune system’s pivotal role in cancer pathogenesis, including CRC.”
BackgroundUnderstanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334 · cited 1×
“Interestingly, tumor cells take advantage of this inhibitory effect in order to induce T-cell tolerance and exhaustion [86].”
BackgroundClinical Relevance of Microsatellite Instability in Colorectal Cancer
de la Chapelle, A., & Hampel, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0652 · Cited by 332 · cited 1×
“Despite this, the mismatch repair (MMR) system is responsible for correcting these errors [32,33].”
BackgroundGuidoboni, M., Gafà, R., Viel, A., Doglioni, C., Russo, A., Santini, A., Del Tin, L., Macrì, E., Lanza, G., Boiocchi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61695-1 · Cited by 322 · cited 1×
“In the case of dMMR/MSI-H CRCs, there is heightened immunogenicity, leading to a significantly increased number of tumor-infiltrating CD8+ T lymphocytes (TILs) and a good prognosis [68,69].”
BackgroundDomingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308 · cited 2×
“In fact, it is believed that at the early stages of neoplastic transformation, telomere shortening reaches a critical length, at which senescence would be triggered.”
BackgroundBellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307 · cited 1×
“This is possible because of the JAK1/JAK2 and STAT1 pathways, leading to tumor cell survival and disease progression [99,100].”
BackgroundMicrosatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 306 · cited 1×
“For an immune cell to recognize a neoplastic cell, the latter must express modified molecules on its surface, typically proteins resulting from DNA mutations or epigenetic alterations [58,59].”
BackgroundDong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
CAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303 · cited 1×
“Detailed information about these trials can be found on the ClinicalTrials.gov website (NCT03935893, NCT04426669, NCT03610490, NCT02980146, NCT01174121, NCT05573035, NCT05902520, NCT05610592, NCT04622423, NCT05524012, NCT03960021, NCT03904537, NCT00019084, NCT05576077).”
Hedgehog Signaling: From Basic Biology to Cancer Therapy
Wu, F., Zhang, Y., Sun, B., McMahon, A. P., & Wang, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.02.010 · Cited by 302 · cited 1×
“The PD-1/PD-L1 axis can interact with various pathways, including MAPK, PI3K/AKT, WNT, JAK/STAT, Hedgehog (Hh), and NF-κ B, ultimately contributing to tumor progression [102–108].”
BackgroundTumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299 · cited 2×
“CD8+ T cells and CD4+ effector T cells have demonstrated anti-cancer potential, while regulatory T cells (CD4+ CD25+ Tregs) have been shown to be able to contribute to the attenuated immune response exhibited in cancer [65,66].”
BackgroundBi, X.-W., Wang, H., Zhang, W.-W., Wang, J.-H., Liu, W.-J., Xia, Z.-J., Huang, H.-Q., Jiang, W.-Q., Zhang, Y.-J., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0341-7 · Cited by 297
Hug, N., & Lingner, J. (2006) · Chromosoma · doi:10.1007/s00412-006-0067-3 · Cited by 291 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundCurrent status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288 · cited 1×
“CRC exhibiting a dMMR/MSI-H profile tends to be located in the right colon, while a constellation of unfavorable characteristics such as distant lymph node metastases, peritoneal cavity spread, mucus secretion, and poor differentiation accompanies it [41,42].”
BackgroundComparison of telomere length measurement methods
Lai, T.-P., Wright, W. E., & Shay, J. W. (2018) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0451 · Cited by 288 · cited 1×
“Bertorelle et al. showed that stage II CRC patients with lower levels of hTERT had better OS, while its presence at higher levels was correlated with a poor response to chemotherapy (as an independent prognostic factor) and with a higher risk of disease recurrence and death [207].”
BackgroundVan den Eynde, M., Mlecnik, B., Bindea, G., Fredriksen, T., Church, S. E., Lafontaine, L., Haicheur, N., Marliot, F., Angelova, M., Vasaturo, A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.003 · Cited by 281 · cited 1×
“However, during each mitotic cell division, DNA polymerases are unable to fully replicate the lagging strand of telomere DNA at the chromosome end, resulting in an annual telomere shortening rate of approximately 20–40 base pairs [170,171].”
BackgroundAntoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00274-1 · Cited by 280 · cited 1×
“In order to overcome this resistance, a therapeutic armamentarium consisting of ICIs and anti-cancer agents with immunomodulatory effects (e.g., anti-VEGFR or anti-EGFR) has been proposed to enhance the immunogenic profile of these lesions and make checkpoint blockade more effective [45,46].”
BackgroundLiu, Z., Li, Q., Li, K., Chen, L., Li, W., Hou, M., Liu, T., Yang, J., Lindvall, C., Björkholm, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.441 · Cited by 276 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundHarris, J. E., Ryan, L., Hoover, H. C., Stuart, R. K., Oken, M. M., Benson, A. B., Mansour, E., Haller, D. G., Manola, J., & Hanna, M. G. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.148 · Cited by 273 · cited 2×
“Such an example is the CEA/TRICOM vaccine which utilizes CEA as the target protein and combines this with three co-stimulatory molecules (TRICOM) B7.”
BackgroundMethodShaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization
Lim, C. J., & Cech, T. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00328-y · Cited by 273 · cited 1×
“Various mechanisms have been identified to alter hTERT gene expression, including methylation of its promoter, mutational changes within the promoter, amplifications, and structural variations [193].”
BackgroundCurrent and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272 · cited 1×
“…to enhance the activity of effector T cells while suppressing regulatory T cells, resulting in net inhibition of tumor progression Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · cited 1×
“This can be achieved because DCs have the potential to activate T cells through antigen presentation by MHC.”
BackgroundGuilleret, I., Yan, P., Grange, F., Braunschweig, R., Bosman, F. T., & Benhattar, J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10593 · Cited by 260 · cited 1×
“Antisense oligonucleotides targeting EGFR have demonstrated significant inhibition of TA, along with TL reduction in various cell lines [216].”
BackgroundPrognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., & Thibodeau, S. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1489 · Cited by 251 · cited 1×
“Additionally, identifying this mutation indicates a poorer outcome in both stage II and III CRC cases [48] Specifically, the presence of the BRAFV600E mutation predicts an unfavorable prognosis in right-sided microsatellite stable (MSS) CRC and undervalued effects of systemic treatment regardless…”
BackgroundAdvances in immunotherapy for colorectal cancer: a review
Golshani, G., & Zhang, Y. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820917527 · Cited by 236
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Telomerase regulation and stem cell behaviour
Flores, I., Benetti, R., & Blasco, M. A. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.03.003 · Cited by 232 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundGowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
PRALL, F. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.01.022 · Cited by 226 · cited 1×
“In the case of dMMR/MSI-H CRCs, there is heightened immunogenicity, leading to a significantly increased number of tumor-infiltrating CD8+ T lymphocytes (TILs) and a good prognosis [68,69].”
BackgroundViral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222 · cited 1×
“This, in turn, allows them to be potentially sensitive to immune checkpoint inhibition [166].”
BackgroundAndre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00064-4 · Cited by 209 · cited 1×
“Pembrolizumab, another anti-PD1 moAb, received approval on 29 June 2020, as a first-line treatment for patients with unresectable or metastatic MSI-H/dMMR CRC based on the KEYNOTE-177 study [124].”
BackgroundSon, N. H., Murray, S., Yanovski, J., Hodes, R. J., & Weng, N.-P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1191 · Cited by 200 · cited 1×
“Simultaneously, TL and TA have already demonstrated their clinical relevance as prognostic and/or predictive biomarkers of response in CRC therapy, while therapeutic strategies targeting hTERT are also under scrutiny.”
BackgroundAndre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.18_suppl.lba4 · Cited by 194 · cited 1×
“Furthermore, the KEYNOTE-177 phase III study showed pembrolizumab’s increased efficiency over first-line systemic treatment with or without additional targeted therapy, irrespective of BRAF mutational status [52].”
BackgroundImpact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 190 · cited 1×
“Monocytes recruited to the site, particularly DCs and macrophages, destroy tumor cells and transport tumor-associated antigens on their surface, initiating a specific cytolytic T-cell response targeted against the tumor [61].”
BackgroundPatterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee, L. H., Cavalcanti, M. S., Segal, N. H., Hechtman, J. F., Weiser, M. R., Smith, J. J., Garcia-Aguilar, J., Sadot, E., Ntiamoah, P., Markowitz, A. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.139 · Cited by 186 · cited 1×
“Nevertheless, the expression of PD-L1 in mCRC is not associated with an immunotherapy response [110].”
BackgroundSpeetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185 · cited 1×
“POLE and POLD1 enzymes play pivotal roles in DNA replication, crucial for synthesizing and repairing DNA.”
BackgroundInducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178 · cited 1×
“It has an extracellular region with two domains (Ig-and IgC) consisting of 290 amino acids [95].”
BackgroundCytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 178 · cited 1×
“Two human monoclonal antibodies targeting CTLA-4 have been developed for patient use: MDX-010, also known as ipilimumab and marketed as Yervoy, and CP-675, also known as tremelimumab [128,129].”
BackgroundCTLA-4 trafficking and surface expression
Valk, E., Rudd, C. E., & Schneider, H. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.011 · Cited by 177 · cited 1×
“In humans, three isoforms are produced through gene splicing: full-length CTLA-4, soluble CTLA-4, and forms involving exon 1 and exon 4 [112].”
BackgroundCurrent approaches in dendritic cell generation and future implications for cancer immunotherapy
Tuyaerts, S., Aerts, J. L., Corthals, J., Neyns, B., Heirman, C., Breckpot, K., Thielemans, K., & Bonehill, A. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0334-z · Cited by 177 · cited 1×
“Additionally, they demonstrate a similar enrichment of CD8+ T cells as observed in tumors with dMMR/MSI-H phenotypes, suggesting a similar underlying biology between these two subgroups of CRC tumors [167].”
BackgroundCTLA‐4: a key regulatory point in the control of autoimmune disease
Scalapino, K. J., & Daikh, D. I. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00639.x · Cited by 176 · cited 1×
“Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a pivotal inhibitory receptor that modulates T-cell function and plays a crucial role in the initial phase of immune responses [111].”
BackgroundTelomere shortening and ageing
Jiang, H., Ju, Z., & Rudolph, K. L. (2007) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-007-0480-0 · Cited by 165 · cited 1×
“The correlation between TL and cancer has been widely demonstrated, with more than 6000 peer-reviewed scientific and clinical publications in this specific field.”
BackgroundMAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
Stutvoet, T. S., Kol, A., de Vries, E. G., de Bruyn, M., Fehrmann, R. S., Terwisscha van Scheltinga, A. G., & de Jong, S. (2019) · The Journal of Pathology · doi:10.1002/path.5280 · Cited by 162
Zhao, R., Song, Y., Wang, Y., Huang, Y., Li, Z., Cui, Y., Yi, M., Xia, L., Zhuang, W., Wu, X., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12571 · Cited by 161 · cited 1×
“The PD-1/PD-L1 axis can interact with various pathways, including MAPK, PI3K/AKT, WNT, JAK/STAT, Hedgehog (Hh), and NF-κ B, ultimately contributing to tumor progression [102–108].”
BackgroundThe Role of Telomere Biology in Cancer
Xu, L., Li, S., & Stohr, B. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164030 · Cited by 160 · cited 2×
“Evidence suggests that telomere shortening can be triggered by age-independent immune senescence that is caused by tumor-associated inflammation [223].”
BackgroundCorrelations between microsatellite instability and the biological behaviour of tumours
Yang, G., Zheng, R.-Y., & Jin, Z.-S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03053-4 · Cited by 160 · cited 1×
“MSI is identified as an alteration of microsatellite length caused by the insertion or deletion of a repetitive unit, allowing for new microsatellite alleles to be formed [34].”
BackgroundPD-1 and cancer: molecular mechanisms and polymorphisms
Salmaninejad, A., Khoramshahi, V., Azani, A., Soltaninejad, E., Aslani, S., Zamani, M. R., Zal, M., Nesaei, A., & Hosseini, S. M. (2018) · Immunogenetics · doi:10.1007/s00251-017-1015-5 · Cited by 159 · cited 1×
“Another interesting way that PD-1 promotes survival and proliferation of cancer cells is via negative interference with the immune response [94].”
BackgroundCytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool
van de Berg, P. J. E. J., Griffiths, S. J., Yong, S.-L., Macaulay, R., Bemelman, F. J., Jackson, S., Henson, S. M., ten Berge, I. J. M., Akbar, A. N., & van Lier, R. A. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903442 · Cited by 157 · cited 1×
“(3) A suppression of immune responses is exhibited by the interplay of PD-1 and PD-L1/PD-L2, inducing a minimized function of T effector cells over immune responses.”
BackgroundDoi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., Sakamoto, N., Katada, K., Kamada, K., Uchiyama, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5399 · Cited by 149
The association between telomere length and cancer risk in population studies
Zhu, X., Han, W., Xue, W., Zou, Y., Xie, C., Du, J., & Jin, G. (2016) · Scientific Reports · doi:10.1038/srep22243 · Cited by 146 · cited 1×
“Furthermore, TL has emerged as a potential predictive biomarker for the clinical outcome of anti-EGFR monoclonal antibody therapy in patients with KRAS wild-type metastatic CRC.”
BackgroundImmunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine
Berd, D., Sato, T., Maguire, H., Kairys, J. C., & Mastrangelo, M. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.043 · Cited by 144 · cited 1×
“Viral vector vaccines: Due to the relatively low stimulating capacity of peptide antigen vaccines, several teams have tried to augment the generated immune response via the use of viral or bacterial vectors.”
BackgroundGatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016) · Familial Cancer · doi:10.1007/s10689-016-9884-6 · Cited by 141 · cited 1×
“Therefore, the presence of MSI indicates dMMR and hypermutability of cells [35].”
BackgroundToon, C. W., Walsh, M. D., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R. J., Clendenning, M., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828f233d · Cited by 136
Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review)
Νikolouzakis, Τ. Κ., Vassilopoulou, L., Fragkiadaki, P., Sapsakos, T. M., Papadakis, G., Spandidos, D. A., Tsatsakis, A. M., & Tsiaoussis, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6330 · Cited by 136 · cited 1×
“In summary, ample evidence supports telomerase as a useful marker for monitoring and predicting outcomes in CRC [207].”
BackgroundSelf-citationActivity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
Keler, T., Halk, E., Vitale, L., O’Neill, T., Blanset, D., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T., Lonberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131 · cited 1×
“Monoclonal antibodies targeting PD-1/PD-L1 interactions have been demonstrated to enhance T cell activity against cancer cells by restoring their activation, proliferation, function, and downstream immune signaling [123].”
BackgroundActivator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 131 · cited 1×
“However, it is well established that neoplastic cells exploit the regulatory action of the c-FOS subunit of Activator protein 1 (AP1) by increasing its expression, thereby upregulating PD-1 expression [93].”
BackgroundFucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004001 · Cited by 129 · cited 1×
“Nevertheless, despite the theory of telomere attrition seeming logical, it is not able to explain senescence in non-proliferating, quiescent, or terminally differentiated cells, suggesting a more complicated pathway [174].”
BackgroundReplicative senescence of CD8 T cells: Effect on human ageing
Effros, R. B. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2003.09.024 · Cited by 127 · cited 1×
“…mCRC. Numerous investigations are ongoing to broaden the applicability of CRC immunotherapy, exploring additional biomarkers or microenvironments that modulate the anti-tumor immune response and evaluating immunotherapy, particularly ICIs, as both a primary and standalone mode of CRC treat-ment.”
BackgroundLi, X., Yao, X., Wang, Y., Hu, F., Wang, F., Jiang, L., Liu, Y., Wang, D., Sun, G., & Zhao, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059064 · Cited by 127 · cited 1×
“…MMR defects can arise from somatic mutations, epigenetic silencing (such as hypermethylation of the hMLH1 promoter in sporadic cases), or germline genetic alterations (as seen in Lynch syndrome), resulting in MSI due to point mutations in MMR genes like hMSH2, hMSH6, hMLH1, PMS2, and PMS1 [36].”
BackgroundRampazzo, E., Bertorelle, R., Serra, L., Terrin, L., Candiotto, C., Pucciarelli, S., Bianco, P. D., Nitti, D., & De Rossi, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605644 · Cited by 125 · cited 1×
“It has been shown that a variety of both normal and neoplastic cells can secrete them (among which are CRC cells) into the microenvironment from where they enter the bloodstream.”
BackgroundNext-generation peptide vaccines for advanced cancer
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013) · Cancer Science · doi:10.1111/cas.12050 · Cited by 124 · cited 1×
“POLE and POLD1 enzymes play pivotal roles in DNA replication, crucial for synthesizing and repairing DNA.”
BackgroundTelomeres: The silence is broken
Azzalin, C. M., & Lingner, J. (2008) · Cell Cycle · doi:10.4161/cc.7.9.5836 · Cited by 123 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundGuo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122 · cited 1×
“However, during each mitotic cell division, DNA polymerases are unable to fully replicate the lagging strand of telomere DNA at the chromosome end, resulting in an annual telomere shortening rate of approximately 20–40 base pairs [170,171].”
BackgroundSchneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737423 · Cited by 116 · cited 1×
“The downstream signaling of CTLA-4 involves the induction of NF-κ B, AP-1, and clustering of zeta chain-associated protein kinase 70 (ZAP-70), which are key molecules in TCR signaling pathways [117].”
BackgroundYochum, G. S., Cleland, R., & Goodman, R. H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00744-08 · Cited by 115 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundGauthier, J., & Yakoub‐Agha, I. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2017.08.003 · Cited by 111 · cited 1×
“As of January 2024, there are 14 clinical trials underway to assess the feasibility and safety of TIL cells for CRC treatment.”
BackgroundColon cancer and the immune system: The role of tumor invading T cells
Waldner, M. J., Schimanski, C.-C., & Neurath, M.-F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i45.7233 · Cited by 111 · cited 2×
“…I antigens), activating suppressor T cells, manipulating death receptor signaling responses, This process is encapsulated by the “three Es of cancer immunoediting”: equilibrium, escape, and elimination [73]. secreting immunosuppressive cytokines, and inducing apoptosis of activated T cells [67].”
BackgroundTurcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107 · cited 1×
“Presentation of the main categories of immune-mediated anti-tumor vaccine platforms along with their advantages and disadvantages.”
BackgroundImmune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Abdoli Shadbad, M., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 107 · cited 1×
“Furthermore, the CTLA-4/CD80, CD86 axis established between immune cells and tumor cells has been implicated in attenuating anti-tumoral immune responses in the tumor microenvironment [118].”
BackgroundTaylor, A., Rothstein, D., & Rudd, C. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0491 · Cited by 106
Garcia‐Aranda, C., de Juan, C., Diaz‐Lopez, A., Sanchez‐Pernaute, A., Torres, A., Diaz‐Rubio, E., Balibrea, J., Benito, M., & Iniesta, P. (2006) · Cancer · doi:10.1002/cncr.21625 · Cited by 105
Differences and evolution of the methods for the assessment of microsatellite instability
Laghi, L., Bianchi, P. P., & Malesci, A. (2008) · Oncogene · doi:10.1038/onc.2008.217 · Cited by 103 · cited 1×
“Based on this panel, MSI is categorized into three groups: MSI-low (MSI-L), where 10–30% of the loci are unstable; MSI-high (MSI-H), which exhibits ≥ 30% unstable loci; and microsatellite stable (MSS), with <10% unstable loci [38].”
BackgroundBilusic, M., Heery, C. R., Arlen, P. M., Rauckhorst, M., Apelian, D., Tsang, K. Y., Tucker, J. A., Jochems, C., Schlom, J., Gulley, J. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1505-8 · Cited by 102 · cited 1×
“This association has been attributed to the presence of an immune-suppressive environment within serous cavities, potentially hindering the efficacy of immunotherapy [165].”
BackgroundRise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
Wang, H. B., Yao, H., Li, C. S., Liang, L. X., Zhang, Y., Chen, Y. X., Fang, J., & Xu, J. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12538 · Cited by 100 · cited 1×
“Overall, PD-L1 expression has been linked to poor clinical outcomes, being more common in mCRC [109].”
BackgroundHonda, M., Mengesha, E., Albano‐Aluquin, S., Nichols, W. S., Wallace, D. J., Al, M., Klinenberg, J. R., & Linker‐Israeli, M. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5023 · Cited by 99 · cited 1×
“…mCRC. Numerous investigations are ongoing to broaden the applicability of CRC immunotherapy, exploring additional biomarkers or microenvironments that modulate the anti-tumor immune response and evaluating immunotherapy, particularly ICIs, as both a primary and standalone mode of CRC treat-ment.”
BackgroundTumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95 · cited 1×
“Detailed information about these trials can be found on the ClinicalTrials.gov website (NCT03935893, NCT04426669, NCT03610490, NCT02980146, NCT01174121, NCT05573035, NCT05902520, NCT05610592, NCT04622423, NCT05524012, NCT03960021, NCT03904537, NCT00019084, NCT05576077).”
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92 · cited 1×
“Nonetheless, it has been proved that this phenotype also has increased immunogenic properties inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [12,43].”
BackgroundTerrin, L., Rampazzo, E., Pucciarelli, S., Agostini, M., Bertorelle, R., Esposito, G., DelBianco, P., Nitti, D., & De Rossi, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0478 · Cited by 91 · cited 2×
“Additionally, downstream targets of EGFR signaling, such as the hypoxia-inducible factor 1-alpha (HIF1-α ) and the PI3K/AKT pathway, contribute to the transcriptional regulation of hTERT, further linking EGFR activation to telomerase regulation [218].”
BackgroundTelomerase efficiently elongates highly transcribing telomeres in human cancer cells
Farnung, B. O., Brun, C. M., Arora, R., Lorenzi, L. E., & Azzalin, C. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035714 · Cited by 91 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundInagaki, A., Ishida, T., Ishii, T., Komatsu, H., Iida, S., Ding, J., Yonekura, K., Takeuchi, S., Takatsuka, Y., Utsunomiya, A., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21688 · Cited by 91 · cited 1×
“Nonetheless, anti-tumor immunity is not always elucidated, as T cells can also lead to cancer progression [64].”
BackgroundSvrcek, M., Lascols, O., Cohen, R., Collura, A., Jonchère, V., Fléjou, J.-F., Buhard, O., & Duval, A. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.12.008 · Cited by 90 · cited 1×
“The coexistence of the BRAFV600E mutation with deficient mismatch repair (dMMR) strongly suggests a sporadic tumor, obviating the need for oncogenetic referral [47].”
BackgroundTelomerase and telomeres in aging theory and chronographic aging theory (Review)
Razgonova, M., Zakharenko, A., Golokhvast, K., Thanasoula, M., Sarandi, E., Nikolouzakis, K., Fragkiadaki, P., Tsoukalas, D., Spandidos, D., & Tsatsakis, A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11274 · Cited by 89 · cited 2×
“In fact, cancers at lower stages tend to have shorter telomeres in contrast to advanced and metastatic cancers [194].”
BackgroundSelf-citationRole of TERRA in the regulation of telomere length
Wang, C., Zhao, L., & Lu, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10528 · Cited by 89 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundRisk of Solid Cancer after Treatment of Testicular Germ Cell Cancer in the Platinum Era
Groot, H. J., Lubberts, S., de Wit, R., Witjes, J. A., Kerst, J. M., de Jong, I. J., Groenewegen, G., van den Eertwegh, A. J. M., Poortmans, P. M., Klümpen, H.-J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.4174 · Cited by 88 · cited 1×
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53–56].”
MethodTelomeres and immune competency
Weng, N.-P. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.05.001 · Cited by 87 · cited 1×
“However, it is also well established that immune responses may be negatively affected in cases of telomere attrition [27,28].”
BackgroundGarcía, J. M., García, V., Peña, C., Domínguez, G., Silva, J., Diaz, R., Espinosa, P., Citores, M. J., Collado, M., & Bonilla, F. (2008) · RNA · doi:10.1261/rna.755908 · Cited by 86 · cited 1×
“Integrating TL into biomarker screening alongside Ras mutations could refine patient selection for anti-EGFR therapy, optimizing treatment efficacy [219].”
MethodThe association of female and male infertility with telomere length (Review)
Vasilopoulos, E., Fragkiadaki, P., Kalliora, C., Fragou, D., Docea, A., Vakonaki, E., Tsoukalas, D., Calina, D., Buga, A., Georgiadis, G., et al. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4225 · Cited by 84 · cited 1×
“In fact, cancers at lower stages tend to have shorter telomeres in contrast to advanced and metastatic cancers [194].”
BackgroundSelf-citationTelomeres, telomerase and colorectal cancer
Bertorelle, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1940 · Cited by 82 · cited 1×
“…offers another avenue for anti-telomerase inhibition by targeting telomerase-positive malignant cells. hTERT serves as a tumor-associated antigen, generating peptides that, when presented with class I major histocompatibility molecules, can stimulate cytotoxic T-lymphocytes to attack cancer cells.”
BackgroundBertorelle, R., Briarava, M., Rampazzo, E., Biasini, L., Agostini, M., Maretto, I., Lonardi, S., Friso, M. L., Mescoli, C., Zagonel, V, et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.602 · Cited by 77 · cited 11×
“Integrating TL into biomarker screening alongside Ras mutations could refine patient selection for anti-EGFR therapy, optimizing treatment efficacy [219].”
BackgroundInfluentialAndré, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 76 · cited 1×
“The BRAFV600E mutation is frequently linked with the hy-permethylator phenotype (CpG island methylator phenotype), which is able to induce MSI-H status via hypermethylation of the MLH1 gene promoter [50].”
BackgroundRole of telomere length in human carcinogenesis (Review)
Tsatsakis, A. M., Oikonomopoulou, T., Νikolouzakis, Τ. Κ., Vakonaki, E., Tzatzarakis, M. N., Flamourakis, M., Renieri, E. A., Fragkiadaki, P., Iliaki, E., Bachlitzanaki, M., et al. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5526 · Cited by 70
Self-citationGameiro, S. R., Higgins, J. P., Dreher, M. R., Woods, D. L., Reddy, G., Wood, B. J., Guha, C., & Hodge, J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070417 · Cited by 69 · cited 1×
“POLE-mutated tumors are characterized by certain elements such as infiltration of CD8+ T cells at higher rates, greater expression of cytotoxic markers, and upregulation of immune checkpoints in contrast to POLE wild-type pMMR/MSS tumors.”
ResultTelomere Length Maintenance, Shortening, and Lengthening
Zhao, Z., Pan, X., Liu, L., & Liu, N. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24537 · Cited by 66 · cited 1×
“Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [21,24,27,29,133].”
BackgroundVaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64 · cited 1×
“Recent findings suggest that assessing the densities of T and B cells within CRC tumors offers higher accuracy compared to evaluating PD-L1 expression alone in predicting the efficacy of immunotherapy.”
ResultBorelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62 · cited 4×
“[12,15,16].”
BackgroundInfluentialKawaguchi, T. (2005) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1568006053005038 · Cited by 62
Recent Patents on Anti-Telomerase Cancer Therapy
Agrawal, A., Dang, S., & Gabrani, R. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212798357958 · Cited by 61 · cited 2×
“Additionally, the proinflammatory milieu of tumors and their microenvironment may add to the overall negative impact of telomere shortening.”
BackgroundLi, C., Li, W., Xiao, J., Jiao, S., Teng, F., Xue, S., Zhang, C., Sheng, C., Leng, Q., Rudd, C. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404578 · Cited by 60 · cited 1×
“Specifically, c-FOS connects to special areas in the CR-B region, enhancing PD-1 expression and stimulating T-cell receptors following antigen detection from naive T cells [92].”
BackgroundToon, C. W., Chou, A., DeSilva, K., Chan, J., Patterson, J., Clarkson, A., Sioson, L., Jankova, L., & Gill, A. J. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.200 · Cited by 59 · cited 2×
“…dMMR/BRAFV600E( − ) tumors exhibit improved overall survival (OS) compared to dMMR/BRAFV600E(+) and proficient MMR (pMMR)/BRAFV600E( − ) or pMMR/BRAFV600E(+) tumors [49,51], the presence of the BRAFV600E mutation does not predict outcomes for patients who have MSI-H mCRC that is managed with ICIs.”
BackgroundClinical Relevance of Telomere Status and Telomerase Activity in Colorectal Cancer
Fernández‐Marcelo, T., Sánchez-Pernaute, A., Pascua, I. P., de Juan, C., Head, J., Torres, A.-J., & Iniesta, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149626 · Cited by 59
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56 · cited 2×
“The intracellular signaling domain (that comprises CD3 ζ and various synergistic proteins) has the potential to propagate immune responses that are specific to antigens and directly influence the effectiveness of CARs in activating T cells [135].”
BackgroundBreaking Bottlenecks for the TCR Therapy of Cancer
Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52 · cited 1×
“Interestingly, adoptive cell therapy (ACT) has demonstrated promising results in cases with these characteristics [17].”
BackgroundKunimura, C., Kikuchi, K., Ahmed, N., Shimizu, A., & Yasumoto, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201916 · Cited by 50 · cited 1×
“According to the above observations, it can be stated that telomere attrition in blood leukocytes of both lineages (myeloid and lymphoid) is a fact, with TL being dependent upon age and differentiation.”
BackgroundDendritic cell vaccine therapy for colorectal cancer
Wooster, A. L., Girgis, L. H., Brazeale, H., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48 · cited 1×
“Additionally, they demonstrate a similar enrichment of CD8+ T cells as observed in tumors with dMMR/MSI-H phenotypes, suggesting a similar underlying biology between these two subgroups of CRC tumors [167].”
BackgroundThe Immune Landscape of Colorectal Cancer
Mezheyeuski, A., Micke, P., Martín-Bernabé, A., Backman, M., Hrynchyk, I., Hammarström, K., Ström, S., Ekström, J., Edqvist, P.-H. D., Sundström, M., et al. (2021) · Cancers · doi:10.3390/cancers13215545 · Cited by 48 · cited 2×
“5 of 25 evaluating specific immunologic parameters (such as Immunoscore ® ) have been developed [72]. infiltration, is mutational load (Figure 1).”
BackgroundCohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., & André, T. (2021) · Cancers · doi:10.3390/cancers13051149 · Cited by 47 · cited 1×
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53–56].”
MethodHeeg, S., Hirt, N., Queisser, A., Schmieg, H., Thaler, M., Kunert, H., Quante, M., Goessel, G., von Werder, A., Harder, J., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01796.x · Cited by 46 · cited 2×
“The authors assumed that the observed difference in OS can be explained by the fact that shorter telomeres may be associated with increased non-tumor-related mortality.”
BackgroundQin, H., Valentino, J., Manna, S., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A., O'Malley, B. W., & Chatterjee, S. K. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0493 · Cited by 44
Common mental disorders and association with telomere length (Review)
Vakonaki, E., Tsiminikaki, K., Plaitis, S., Fragkiadaki, P., Tsoukalas, D., Katsikantami, I., Vaki, G., Tzatzarakis, M., Spandidos, D., & Tsatsakis, A. (2018) · Biomedical Reports · doi:10.3892/br.2018.1040 · Cited by 44
Self-citationKroupa, M., Rachakonda, S. K., Liska, V., Srinivas, N., Urbanova, M., Jiraskova, K., Schneiderova, M., Vycital, O., Vymetalkova, V., Vodickova, L., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0525-3 · Cited by 41 · cited 2×
“Researchers have identified TA as an independent prognostic factor for DFS, recurrence, and OS in CRC patients, with high levels of TERT and/or TA typically associated with poorer prognosis [204].”
BackgroundResultInfluentialPeptide Vaccine Therapy in Colorectal Cancer
Bartnik, A., Nirmal, A. J., & Yang, S.-Y. (2012) · Vaccines · doi:10.3390/vaccines1010001 · Cited by 39 · cited 1×
“Their findings revealed that the presence of peritoneal metastases and ascites correlated with poorer outcomes in a cohort of 502 patients with dMMR/MSI-H mCRC treated with ICIs.”
BackgroundColorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39 · cited 2×
“Additionally, they demonstrate a similar enrichment of CD8+ T cells as observed in tumors with dMMR/MSI-H phenotypes, suggesting a similar underlying biology between these two subgroups of CRC tumors [167].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that is often used to treat MSI High (MSI-H) or dMMR tumors [37].”
Hedayati, N., Safari, M. H., Milasi, Y. E., Kahkesh, S., Farahani, N., Khoshnazar, S. M., Dorostgou, Z., Alaei, E., Alimohammadi, M., Rahimzadeh, P., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02471-w · Cited by 81
“Conventional therapeutic strategies for CRC include chemotherapy, radiotherapy, surgery, and targeted therapy [123, 124].”
Rahimi, A. R., Baghernejadan, Z., Hazrati, A., Malekpour, K., Samimi, L. N., Najafi, A., Falak, R., & Khorramdelazad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118014 · Cited by 44
Liu, C.-J., Wang, L., & Tsai, F. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030176 · Cited by 38
“These drugs target hormone receptors on the surface or inside tumor cells, thereby blocking hormone binding or inhibiting hormone production to reduce tumor proliferation.”
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 25
Metadata
- Authors
- Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A.
- Affiliations
- Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Greece
- University Hospital of Heraklion (GR)
- University of Medicine and Pharmacy of Craiova (RO)
- University of Crete (GR)
- Corresponding author
- Docea, Anca Oana
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-05-24
- Volume
- 16
- Issue
- 11
- Pages
- 1995
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11171065
- OpenAlex
- W4398784015
- Semantic Scholar
- c95ad9da0dd0edfa1ade7cb55cb7fd46410f4713
- Cited by
- 37
- References
- 234
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 4
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, immunotherapy, immune checkpoint inhibitors, adoptive immunotherapy, telomere length, telomere dysfunction, chromosomal instability, carcinogenesis, cancer treatment trends
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.